blood-cancer
An optofluidic chip using laser light scatter patterns and SVM machine learning classified drug-resistant vs drug-sensitive leukemia cells with 91.1% accuracy in about 20 minutes. The label-free method requires no staining, making it practical for rapid clinical diagnostics.
blood-cancer
BET inhibitors (drugs targeting BET bromodomain proteins) showed extraordinary promise in early cancer research — they could suppress the expression of potent oncogenes like MYC. But clinical trials have repeatedly disappointed, with patients not responding as expected. A new study may have found…
blood-cancer
As cancer treatments have improved and more patients survive their primary cancers, a concerning side effect has emerged: therapy-related acute myeloid leukemia (tAML), a severe leukemia caused by the DNA-damaging effects of chemotherapy and radiation used to treat other cancers.
blood-cancer
Myelofibrosis (MF) is the most severe type of myeloproliferative neoplasm, characterized by scarring of the bone marrow that eventually destroys normal blood cell production. Current treatments rarely reverse this fibrosis, and progress has been hampered by a lack of good animal models.
blood-cancer
Acute myeloid leukemia (AML) is notoriously hard to treat partly because leukemic stem cells — the root source of the disease — can develop resistance to therapies. This study investigated whether these stem cells depend on PI3 kinase (PI3K), a key cell-signaling enzyme. Researchers found that…
blood-cancer
Repurposed cancer drug OTS167 targets newly discovered mitotic kinase in aggressive lymphoma, showing tumor reduction in mice Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma, and many patients aren't cured by standard treatment. Researchers screened a library of kinase inhibitors and stumbled onto an unexpected target: